Identifying new pronostic markers of IBD

Studying the variations in VNN1 expression at different stages of the disease and under therapy, A IBD biobank was generated starting with biopsy samples collected from patients suffering from CD or UC and diagnosed as clinically quiescent (Q) or in active phase of the disease (A). Patients were even not-treated at the period of diagnosis (NT) or responders or not to various therapies such as 5-ASA, anti-TNFalpha biologics (aTNF), corticoids (Cort) or immunosuppressors (IS). Controls were taken from non-inflammatory healthy portions of colon (CTRL). Transcriptome profiling was performed with RNA-Seq.